A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Oct 17, 2012

Astellas Pharma Inc.: Donation of Six Wheelchair Vans by Employee-Run Social Contribution Fund “Flying Star Fund”

Read more about Astellas Pharma Inc.: Donation of Six Wheelchair Vans by Employee-Run Social Contribution Fund “Flying Star Fund”
Oct 3, 2012

Astellas Announces Poster Presentation of SGLT2 Inhibitor (Ipragliflozin) Detailing Efficacy and Safety in Combination with Other Hypoglycemic Agents in Patients with Type 2 Diabetes at the European Association for the Study of Diabetes Meeting

Read more about Astellas Announces Poster Presentation of SGLT2 Inhibitor (Ipragliflozin) Detailing Efficacy and Safety in Combination with Other Hypoglycemic Agents in Patients with Type 2 Diabetes at the European Association for the Study of Diabetes Meeting
Oct 1, 2012

AVEO and Astellas Announce New Data Presented at ESMO 2012 Congress Demonstrating the Safety and Tolerability Profile of Tivozanib in Patients with Advanced Kidney Cancer First Patient Enrolled in TAURUS Patient Preference Study

CAMBRIDGE, Mass. and TOKYO, Japan, October 1, 2012 - AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced new data from the Phase 3 TIVO-1 trial (TIvozanib Versus...

Read more about AVEO and Astellas Announce New Data Presented at ESMO 2012 Congress Demonstrating the Safety and Tolerability Profile of Tivozanib in Patients with Advanced Kidney Cancer First Patient Enrolled in TAURUS Patient Preference Study
Sep 30, 2012

Medivation and Astellas Announce New Data From XTANDI® (enzalutamide) Pivotal Study

-- AFFIRM Study Data Presented Today at European Society of Medical Oncology (ESMO) --

Read more about Medivation and Astellas Announce New Data From XTANDI® (enzalutamide) Pivotal Study
Sep 28, 2012

AVEO and Astellas Announce Submission of New Drug Application for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma

CAMBRIDGE, Mass. and TOKYO, Japan, September 28, 2012 -- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that AVEO has submitted a New Drug Application (NDA) to...

Read more about AVEO and Astellas Announce Submission of New Drug Application for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts